Share This:
Jardiance Asks: Consumer Campaign
Share This:
Boehringer Ingelheim & Eli Lilly and Evoke Health for Jardiance Jardiance Asks: Consumer Campaign An authentic approach successfully engaged type 2 diabetes patients who were unaware of and unreceptive to learning about the link … Read More
CHMP Issues Positive Opinion To Expand Jardiance®, Synjardy® And Glyxambi® Labels To Include Positive Effects On Cardiovascular And Renal Outcomes
Share This:
INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to update … Read More
Novo’s oral semaglutide bests Lilly and Boehringer Ingelheim’s Jardiance in phase 3, but questions remain
Share This:
Even as Novo Nordisk works to steal diabetes market share with its new GLP-1 drug Ozempic, it’s advancing an oral version that could pose another threat to rivals in the field. In a new phase … Read More
FDA Approves Aimovig for Migraine Prevention
Share This:
The U.S. Food and Drug Administration has approved erenumab (Aimovig™, Amgen and Novartis), a first-in-class calcitonin gene-related peptide (CGRP) antagonist, for the prevention of migraine in adults. Erenumab consistently demonstrated an ability to reduce monthly … Read More